Medlineã®2026幎床第2ååææ±ºç®ïŒå£²äžé«11.6%å¢ãç«çœæå€±ã§å©çå§è¿«
MedlineïŒNasdaq: MDLNïŒã¯ã2026幎6æ27æ¥çµäºã®2026幎床第2ååæã«ãçŽå£²äžé«76å8,500äžãã«ïŒåå¹Žåææ¯11.6%å¢ïŒãMedline Inc.åž°å±ã®åžèååŸEPS 0.07ãã«ãèšäžããã調æŽåŸEBITDAã¯13.4%å¢ã®10å6,000äžãã«ãšãªã£ãäžæ¹ãã«ãªãã©ã«ãã¢å·ãã¬ãŒã·ãŒã®ç©æµã»ã³ã¿ãŒç«çœãšè²»çšå¢ã売äžé«æé·ããã³é¢çšéä»ã®æ©æµãäžåããé£çµçŽå©çã¯58.3%æžå°ããã
äž»èŠæ±ºç®ããŒã¿
ãªãŒã¬ããã¯å£²äžé«ã¯11.5%å¢å ãããäž»ãªèŠå ã¯æ¢å顧客ããã®æé·ãšã2025幎ã«ç· çµãã顧客å¥çŽã®å°å ¥ã ã£ããå ±åããŒã¹ã®å£²äžé«ã«ã¯ãIEEPAé¢çšéä»ã«é¢é£ãã顧客ãžã®è¿éèŠè¶é¡8,900äžãã«ã®æ§é€ãåæ ãããã
Medlineã¯é¢çšéä»3å3,200äžãã«ã売äžåäŸ¡ã®æžé¡ãšããŠèšäžããããšãªã©ããã売äžç·å©ççãäžæããããã ããå¶æ¥è²»çšåèšã44.1%å¢å ãããã®äžã«ã¯ãã¬ãŒã·ãŒç©æµã»ã³ã¿ãŒç«çœã«é¢é£ããæå€±3å3,600äžãã«ãå«ãŸãããããå¶æ¥å©ççã¯å€§å¹ ã«äœäžããã
| ææš | 2026幎床第2ååæ | 2025幎床第2ååæ | åå¹Žåææ¯ |
|---|---|---|---|
| çŽå£²äžé« | 76å8,500äžãã« | 68å8,600äžãã« | +11.6% |
| 売äžç·å©çïŒå£²äžç·å©çç | 22å1,500äžãã«ïŒ28.8% | 19å500äžãã«ïŒ27.7% | +16.3%ïŒ+110bp |
| å¶æ¥å©çïŒå¶æ¥å©çç | 3å9,500äžãã«ïŒ5.1% | 6å4,200äžãã«ïŒ9.3% | -38.5%ïŒ-420bp |
| çŽå©çïŒçŽå©çç | 1å3,900äžãã«ïŒ1.8% | 3å3,300äžãã«ïŒ4.8% | -58.3%ïŒ-300bp |
| Medline Inc.åž°å±çŽå©ç | 6,000äžãã« | 3å3,300äžãã« | -82.0% |
| Medline Inc.åž°å±ã®åžèååŸEPS | 0.07ãã« | 該åœãªã | 該åœãªã |
| 調æŽåŸåžèååŸEPS | 0.50ãã« | éé瀺 | 該åœãªã |
| 調æŽåŸEBITDAïŒããŒãžã³ | 10å6,000äžãã«ïŒ13.8% | 9å3,500äžãã«ïŒ13.6% | +13.4%ïŒ+20bp |
調æŽåŸEBITDAãšèª¿æŽåŸåžèååŸEPSã¯éGAAPææšã§ãããéæ¯é æååž°å±çŽå©çã¯7,900äžãã«ã§ãé£çµçŽå©çãšMedline Inc.åž°å±é¡ã®å·®é¡ã説æããã
äºæ¥ããã³ã»ã°ã¡ã³ã奿¥çžŸ
Supply Chain Solutionsã¯äŒç€Ÿå šäœã®å¢ååã®å€§åãçã¿åºããããå©çã®äŒžã³ã¯å£²äžé«æé·ãäžåã£ããMedline Brandã¯å£²äžé«ã®äŒžã³ãããç·©ããã ã£ãäžæ¹ã調æŽåŸEBITDAã¯å€§å¹ ã«å¢å ããé¢çšéä»ã®åœ±é¿ã¯å šãŠåã»ã°ã¡ã³ãã«èšäžãããã
| ã»ã°ã¡ã³ã | 第2ååæçŽå£²äžé« | 売äžé«æé·ç | 調æŽåŸEBITDA | 調æŽåŸEBITDAããŒãžã³ |
|---|---|---|---|---|
| Medline Brand | 35å4,000äžãã« | +6.6% | 10å6,700äžãã«ã+19.9% | 30.1%ïŒå幎åæ26.8%ïŒ |
| Supply Chain Solutions | 41å4,500äžãã« | +16.3% | 2å400äžãã«ã+1.5% | 4.9%ïŒå幎åæ5.6%ïŒ |
Supply Chain Solutionsã®ããŒãžã³ã¯70bpäœäžããŠãããæ¥éãªå£²äžé«æé·ãã»ã°ã¡ã³ãå©çã«æ¯äŸããŠçµã³ä»ããªãã£ãããšã瀺ããæ¬ç€Ÿããã³ãã®ä»ã®è²»çšãã1å5,600äžãã«ãã2å1,100äžãã«ãžå¢å ããã
2026å¹ŽäžæãMedlineã¯æšå®å¹Žéå¥çŽé¡ããŒã¹ã§ãæ°èŠé¡§å®¢å¥çŽç²åŸã®å¹Žéç®æšã®65%è¶ ã確ä¿ããã
é¢çšéä»ã調æŽåŸæ¥çžŸãæŒãäžããäžæ¹ããã¬ãŒã·ãŒç«çœãGAAPå©çãå§è¿«
IEEPAé¢çšã®äŒèšåŠçãšãã¬ãŒã·ãŒç«çœã¯ãGAAPçŽå©çãæžå°ããäžæ¹ã§èª¿æŽåŸEBITDAãå¢å ããäž»ãªçç±ããããã説æãããMedlineã¯é¢çšéä»3å3,200äžãã«ã売äžåäŸ¡ã®æžé¡ãšããŠèªèããé¢é£ãã顧客ãžã®è¿é8,900äžãã«ãçŽå£²äžé«ã®æžé¡ãšããŠèŠè¶èšäžãããããçŽé¡ã§2å4,300äžãã«ã®å©çãçããã
ãã®2å4,300äžãã«ã®å©çã¯ãçŽå©çãšèª¿æŽåŸEBITDAã®åæ¹ã«æ®ã£ããå¯Ÿç §çã«ãäºæ³ãããä¿éºéåååã®ãã¬ãŒã·ãŒç©æµã»ã³ã¿ãŒç«çœæå€±3å3,600äžãã«ã¯ã調æŽåŸEBITDAãžã®èª¿æŽã§å ç®ãæ»ãããéäžæ žè²»çšã«å«ãŸããã
ãããã£ãŠã第2ååæã®èª¿æŽåŸEBITDAã¯é¢çšéä»ã®æ©æµãåããäžæ¹ãç«çœæå€±ãé€å€ããŠããã売äžé«å¢å ã調æŽåŸEBITDAãæ¯ããããå¶æ¥è²»çšã®å¢å ãšé¢çšé¢é£ã³ã¹ãããã®å¹æãäžéšçžæ®ºããã
ãã£ãã·ã¥ãããŒãšè²žåå¯Ÿç §è¡š
2026å¹Žäžæã®å¶æ¥ãã£ãã·ã¥ãããŒã¯ã8å7,900äžãã«ãã28.2%å¢ã®11å2,700äžãã«ãšãªã£ããäž»ã«ç©æµã»ã³ã¿ãŒã®èªååãšãããã£ã³ã°è£œé æœèšãžã®æè³ã«åããèšåæè³2å700äžãã«ãå·®ãåŒããããªãŒãã£ãã·ã¥ãããŒã¯ã37.1%å¢ã®9å2,000äžãã«ã ã£ãã
6æ27æ¥æç¹ã®çŸéããã³çŸéåçç©ã¯ã2025幎æ«ã®19å3,900äžãã«ãã23å2,700äžãã«ãžå¢å ãããäžæ¹ãåšåº«ã¯47å6,900äžãã«ãã46å6,500äžãã«ãžæžå°ãããMedlineã¯çŽæå©åè² åµ100å7,300äžãã«ã調æŽåŸEBITDAã«å¯Ÿãããããã¬ãã¬ããž2.9åãå ±åããã
2026å¹Žéææ¥çžŸèŠéã
Medlineã¯æ¢å顧客ããã³æ°èŠé¡§å®¢ããã®éèŠãèæ¯ã«ãªãŒã¬ããã¯å£²äžé«èŠéããåŒãäžããäžæ¹ã調æŽåŸEBITDAã®ã¬ã³ãžãåŒãäžãããçµå¶é£ã¯å©çèŠéãã®ä¿®æ£ã«ã€ããŠãäžæ±çŽäºã«é¢é£ããæ³å®ä»¥äžã®ã€ã³ãã¬ã远å çãªäºæ¥éå¶æè³ãåè³ªæ¯æ£æ¯åºããªããŒã«ãã£ãã«ã®è»èª¿ãèŠå ãšããŠæããã
| ææš | æŽæ°åŸã®2026幎éæèŠéã | åŸæ¥èŠéã | å€æŽ |
|---|---|---|---|
| ãªãŒã¬ããã¯å£²äžé«æé·ç | 9.0%ïœ10.0% | 8.5%ïœ9.5% | 䞡端ã0.5ãã€ã³ãåŒãäžã |
| 調æŽåŸEBITDA | 33åïœ34åãã« | 35åïœ36åãã« | 䞡端ã2åãã«åŒãäžã |
ãªãŒã¬ããã¯å£²äžé«èŠéãã«ã¯ãé¢çšã«é¢é£ãã顧客ãžã®è¿éãåæ ãããŠããã調æŽåŸEBITDAèŠéãã¯ãå ±åããã第2ååæã®èª¿æŽåŸEBITDAãšç°ãªããIEEPAé¢çšéä»ã«ããå©çãé€å€ããŠããã
æè¿ã®ã€ã³ãµã€ããŒååŒ
æè¿ã®æåºæžé¡ã«ã¯ãçŽæ¥ä¿æã«ãã圹å¡1ä»¶ã®è³Œå ¥ã®ã»ããè€æ°ã®çŽæ¥ã»éæ¥ä¿æã«ãã売åŽãå«ãŸããŠãããå ±åãããååŒã¯éé¡ãšä¿æåœ¢æ ã瀺ããŠããããã€ã³ãµã€ããŒã®ååŒåæ©ã¯é瀺ããŠããªãã
| æ¥ä» | ã€ã³ãµã€ã㌠| ååŒ | ä¿æåœ¢æ | å ±åé¡ |
|---|---|---|---|---|
| 2026幎6æ16æ¥ | Douglas P. Golwas | 1æ ªåœãã36.60ïœ37.05ãã«ã§å£²åŽ | çŽæ¥ä¿æ | $3,677,115 |
| 2026幎6æ5æ¥ | Jessi L. Corcoran | 1æ ªåœãã34.15ãã«ã§è³Œå ¥ | çŽæ¥ä¿æ | $170,750 |
| 2026幎5æ28æ¥ | Hellman & Friedman Capital Partners X Parallel, L.P. | 1æ ªåœãã36.54ãã«ã§å£²åŽ | éæ¥ä¿æ | $1,164,385,709 |
| 2026幎5æ28æ¥ | BX Mozart ML-2 Holdco L.P. | 1æ ªåœãã36.54ãã«ã§å£²åŽ | éæ¥ä¿æ | $1,217,349,994 |
| 2026幎3æ10æ¥ | Carlyle Group Inc. | 1æ ªåœãã41.00ãã«ã§å£²åŽ | éæ¥ä¿æ | $1,070,339,440 |
æè³å®¶ã泚èŠãã¹ããªã¹ã¯
- ç©æµãããã¯ãŒã¯ã®æ··ä¹±ïŒ ãã¬ãŒã·ãŒç«çœã¯ãäºæ³ãããä¿éºéåååã§3å3,600äžãã«ã®æå€±ãçããããéèŠæœèšã®æ··ä¹±ãåãŒãåŸã財åç圱é¿ã瀺ããŠããã
- 売äžé«æé·ã«ããããããç¶ãã³ã¹ãå§åïŒ å¶æ¥è²»çšãé¢çšãã€ã³ãã¬ã®äžæã¯ãGAAPåçæ§ã®äœäžãšèª¿æŽåŸEBITDAèŠéãã®åŒãäžãã«å¯äžããã
- ã»ã°ã¡ã³ãéã§äžåäžãªæ¡ç®æ§ïŒ Supply Chain Solutionsã®å£²äžé«ã¯16.3%å¢å ãããã調æŽåŸEBITDAã¯1.5%å¢ã«ãšã©ãŸããããŒãžã³ã¯äœäžããã
- äºæ¥å·è¡ã®ããã®æ¯åºãšãã£ãã«ã®è»èª¿ïŒ åè³ªæ¯æ£ã顧客éèŠãæ¯ããããã«å¿ èŠãªæè³ããªããŒã«ãã£ãã«ã®è»èª¿ã¯ãåŒãäžãåŸã®å©çèŠéãã«ç¹ã蟌ãŸããŠããã
- 調æŽåŸæ¥çžŸã®æ¯èŒå¯èœæ§ïŒ 第2ååæã®èª¿æŽåŸEBITDAã«ã¯çŽé¡2å4,300äžãã«ã®é¢çšéä»ã«ããå©çãå«ãŸããäžæ¹ãéæèŠéãã¯ãã®å©çãé€å€ããŠããã
ãŸãšã
Medlineã®ç¬¬2ååæã®å£²äžé«æé·ã¯ãæ¢å顧客ã®éèŠãšéå»ã«ç²åŸããå¥çŽã®å°å ¥ãåæ ãããããã¬ãŒã·ãŒç«çœãšå¶æ¥ã³ã¹ãã®äžæã«ããGAAPå©çã¯æžå°ãããé¢çšéä»ã¯å£²äžç·å©ççãšèª¿æŽåŸEBITDAãæ¯ããå ±åæ¥çžŸãšèª¿æŽåŸæ¥çžŸã®éã«å€§ããªå·®ãçãããããä»åŸã®äž»ãªè«ç¹ã¯ã顧客䞻å°ã®å£²äžé«æé·ãã»ã°ã¡ã³ãããŒãžã³ã®æ¹åã«ã€ãªãããããŸãMedlineãåŒãäžãåŸã®EBITDAèŠéãã®ç¯å²å ã§ã€ã³ãã¬ãæ¯æ£ã³ã¹ããäºæ¥éå¶æè³ã管çã§ãããã©ããã§ããã
ãã®èšäºã®äžéšã¯AIã«ãã£ãŠçæã»ç¿»èš³ããã人éã«ããã¬ãã¥ãŒãçµãŠããŸããããã¯äžè¬çãªæ å ±æäŸã®ç®çã§ã®ã¿äœ¿çšãããŠãããæè³ã¢ããã€ã¹ãæ§æãããã®ã§ã¯ãããŸããã
ããããèšäº













ã³ã¡ã³ã (0)
$ãã¿ã³ãã¯ãªãã¯ããã·ã³ãã«ãå ¥åããŠãæ ªåŒãETFããŸãã¯ãã®ä»ã®ãã£ãã«ãŒã·ã³ãã«ããªã³ã¯ããŸãã